Conservative commentator Charlie Kirk shot and killed at Utah event
Spyre Therapeutics (NASDAQ:SYRE), a biotechnology company with a market capitalization of $1 billion, saw its Chief Financial Officer Scott L. Burrows sell 18,428 shares of common stock on September 2, 2025, at prices ranging from $16.26 to $16.30, for a total value of $299639. The stock, currently trading at $16.83, has shown significant volatility this year with a 52-week range of $10.91 to $40.26.
The sale was executed to cover the executive’s tax obligations related to the settlement of 33,738 restricted stock units. Following the transaction, Burrows directly owns 97,994 shares, including 67,476 restricted stock units which vest in two equal installments on September 1, 2026 and 2027. According to InvestingPro, analysts maintain a strong buy consensus on the stock, with targets ranging from $21 to $71. The company currently appears overvalued based on InvestingPro’s Fair Value analysis, with 7 additional exclusive insights available to subscribers.
In other recent news, Spyre Therapeutics announced positive interim Phase 1 results for its investigational monoclonal antibodies SPY002 and SPY072, targeting TL1A for immune-mediated diseases. The company reported that these antibodies were well-tolerated with no serious adverse events and demonstrated a significantly extended half-life. Meanwhile, several analysts have reiterated their positive outlook on Spyre stock. Guggenheim reaffirmed its Buy rating with a $65 price target, noting the company’s continued progress in its inflammatory bowel disease (IBD) treatment pipeline. Stifel also maintained its Buy rating with a $71 price target, citing Spyre’s clinical advancements, particularly with its SKYLINE-UC platform study. Additionally, Leerink Partners reiterated an Outperform rating, emphasizing the importance of Spyre’s anti-TL1A program as a potential best-in-class treatment for IBD. These developments reflect the company’s strategic focus on advancing its clinical programs and potential in developing optimized therapies for immune-mediated conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.